 Aeterna Zentaris Inc. AEZS AEZS the Company, a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that it has regained compliance with the minimum bid price for continued listing on the Nasdaq Capital Market, as the closing bid price of the Companys common stock has been at 1.00 or greater for 10 consecutive trading days. On April 8, 2020, the Company received notice that its common stock failed to maintain a minimum bid price of 1.00 over the previous 30 consecutive business days as required by Nasdaq. Now that the Company has regained compliance with this listing rule, Nasdaq has advised the Company that this matter is now closed. 